Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis.
Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis.
复制标题
微小泌乳素瘤的手术和药物治疗：系统回顾和荟萃分析
DOI：
10.1155/2021/9930059
复制
发表时间：
2021
影响因子：
2.8
通讯作者：
Su Z
中科院分区：
文献类型：
--
作者：
Lu J;Cai L;Wu Z;Lin W;Xu J;Zhu Z;Wang C;Li Q;Su Z
Objective Dopamine agonists (DAs) are recommended as the first-line treatment for prolactinomas; however, tumour recurrence after drug withdrawal remains a clinical problem. Recent studies have reported high remission rates via surgery in microprolactinomas. The aim of this systematic review and meta-analysis was to compare the clinical result of DA treatment with surgery as initial therapy in patients with treatment-naive microprolactinoma. Methods A comprehensive literature search for studies and reports regarding microprolactinoma patients treated with DAs and/or surgery published between January 1970 and November 2020 was conducted using four electronic databases (PubMed, Embase, Google Scholar, and the Cochrane Library). Clinical treatment outcome was evaluated by the biochemical remission of serum prolactin level to normal after treatment. The I2 statistic was used to quantify heterogeneity. Pooled data were analysed according to a random effect model. Results Eighteen studies with 661 patients were included for analysis. The DA treatment group achieved a higher remission rate at ≥12 months follow-up (96% vs. 86%; P=0.019). Surgery showed a higher remission rate than the DA treatment group after the treatment withdrawal (78% vs. 44%; P=0.003). Patients with preoperative prolactin level of ≤200 ng/mL had a higher remission rate than patients with preoperative prolactin level of >200 ng/mL (92% vs. 40%; P=0.029). Conclusion Surgery showed a high remission rate in treatment-naive microprolactinoma patients after treatment withdrawal and may be an alternative first-line treatment strategy in addition to DAs, particularly in patients with a preoperative prolactin level of ≤200 ng/mL.
登录
查看更多内容
影响因子：
2.4
作者：
Akin, Safak;Isikay, Ilkay;Berker, Mustafa
通讯作者：
Berker, Mustafa
影响因子：
4.1
作者：
Hofstetter, Christoph P.;Shin, Benjamin J.;Schwartz, Theodore H.
通讯作者：
Schwartz, Theodore H.
影响因子：
5.2
作者：
Ma Q;Su J;Li Y;Wang J;Long W;Luo M;Liu Q
通讯作者：
Liu Q
影响因子：
4.1
作者：
Amar, AP;Couldwell, WT;Weiss, MH
通讯作者：
Weiss, MH
影响因子：
2
作者：
Andereggen, Lukas;Frey, Janine;Christ, Emanuel
通讯作者：
Christ, Emanuel